脓毒症中的抗血小板药物——整合一切：行动呼吁
Antiplatelet Agents in Sepsis-Putting it all together: A Call to Action.
作者信息
Tiwari Nishant R, Chaudhari Kaustubh S, Sharma Richa, Haas Kevin P, Sharma Vivek R
机构信息
Department of Internal Medicine, Byramjee Jeejeebhoy Government Medical College, Pune, Maharashtra, India.
Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma, USA.
出版信息
Indian J Crit Care Med. 2020 Jun;24(6):483-484. doi: 10.5005/jp-journals-10071-23450.
Abstract
Tiwari NR, Chaudhari KS, Sharma R, Haas KP, Sharma VR. Antiplatelet Agents in Sepsis-Putting it all together: A Call to Action. Indian J Crit Care Med 2020;24(6):483-484.
摘要
蒂瓦里·N·R、乔杜里·K·S、夏尔马·R、哈斯·K·P、夏尔马·V·R。脓毒症中的抗血小板药物——综合考量：行动呼吁。《印度重症监护医学杂志》2020年；24(6):483 - 484。
相似文献
1
Antiplatelet Agents in Sepsis-Putting it all together: A Call to Action.脓毒症中的抗血小板药物——整合一切：行动呼吁
Indian J Crit Care Med. 2020 Jun;24(6):483-484. doi: 10.5005/jp-journals-10071-23450.
2
Polymyxin B Hemoperfusion in Sepsis: A Possible Silver Lining to the Dark Clouds?脓毒症中多黏菌素B血液灌流：黑暗中的一线曙光？
Indian J Crit Care Med. 2024 Oct;28(10):903-905. doi: 10.5005/jp-journals-10071-24816. Epub 2024 Sep 30.
3
Author Reply: Comparison of Norepinephrine and Terlipressin vs Norepinephrine Alone for Management of Septic Shock: A Randomized Control Study.作者回复：去甲肾上腺素与特利加压素联合去甲肾上腺素治疗感染性休克的比较：一项随机对照研究。
Indian J Crit Care Med. 2023 Aug;27(8):603-604. doi: 10.5005/jp-journals-10071-24514.
4
Early Antibiotics in Septic Shock: A Desirable Goal but "Curb Your Enthusiasm".脓毒性休克早期使用抗生素：一个理想目标，但“请克制你的热情” 。
Indian J Crit Care Med. 2023 Jul;27(7):459-460. doi: 10.5005/jp-journals-10071-24494.
5
Comparison of Norepinephrine and Terlipressin vs Norepinephrine Alone for Management of Septic Shock: Few Concerns.去甲肾上腺素与特利加压素联合使用与单独使用去甲肾上腺素治疗感染性休克的比较：顾虑较少。
Indian J Crit Care Med. 2023 Aug;27(8):605. doi: 10.5005/jp-journals-10071-24503.
6
Pediatric Sepsis - Sailing the Unchartered Waters with Omics.小儿脓毒症——借助组学探索未知领域
Indian J Crit Care Med. 2024 Sep;28(9):818-819. doi: 10.5005/jp-journals-10071-24799. Epub 2024 Aug 31.
7
Harmonizing the Septic Shock Terminology: Need of the Hour.统一脓毒症休克术语：当务之急
Indian J Crit Care Med. 2023 Apr;27(4):294-295. doi: 10.5005/jp-journals-10071-24433.
8
Sepsis in Intensive Care Unit: Which Score Predicts Better about Outcome?重症监护病房中的脓毒症：哪种评分对预后的预测更准确？
Indian J Crit Care Med. 2022 Oct;26(10):1072-1073. doi: 10.5005/jp-journals-10071-24337.
9
Guidelines for the Use of Procalcitonin for Rational Use of Antibiotics.降钙素原用于合理使用抗生素的指南。
Indian J Crit Care Med. 2022 Oct;26(Suppl 2):S77-S94. doi: 10.5005/jp-journals-10071-24326.
10
Author Response: Unanswered Questions and Contradictory Statements in the Antibiotics Prescription Guidelines.作者回应：抗生素处方指南中未解答的问题和相互矛盾的陈述。
Indian J Crit Care Med. 2024 Jul;28(7):717-718. doi: 10.5005/jp-journals-10071-24750.
引用本文的文献
1
Platelet P2Y signalling pathway in the dysregulated immune response during sepsis.血小板 P2Y 信号通路在脓毒症免疫失调反应中的作用。
Br J Pharmacol. 2024 Feb;181(4):532-546. doi: 10.1111/bph.16207. Epub 2023 Aug 29.
2
Platelets, Bacterial Adhesins and the Pneumococcus.血小板、细菌黏附素与肺炎球菌
Cells. 2022 Mar 25;11(7):1121. doi: 10.3390/cells11071121.
3
Aspirin or Ticagrelor in Infective Endocarditis: Where Do We Stand?阿司匹林或替格瑞洛用于感染性心内膜炎：我们目前的情况如何？
Front Cell Dev Biol. 2021 Oct 7;9:716302. doi: 10.3389/fcell.2021.716302. eCollection 2021.
本文引用的文献
1
Effects of antiplatelet therapy on the mortality rate of patients with sepsis: A meta-analysis.抗血小板治疗对脓毒症患者死亡率的影响：一项荟萃分析。
J Crit Care. 2019 Apr;50:162-168. doi: 10.1016/j.jcrc.2018.12.004. Epub 2018 Dec 5.
2
Platelet activation and antiplatelet therapy in sepsis: A narrative review.脓毒症中的血小板激活和抗血小板治疗：叙述性综述。
Thromb Res. 2018 Jun;166:28-36. doi: 10.1016/j.thromres.2018.04.007. Epub 2018 Apr 9.
3
Antiplatelet Therapy for Critically Ill Patients: A Pairwise and Bayesian Network Meta-Analysis.危重症患者的抗血小板治疗：一项基于网络的成对和贝叶斯Meta 分析。
Shock. 2018 Jun;49(6):616-624. doi: 10.1097/SHK.0000000000001057.
4
A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.抗血小板治疗对人类内毒素血症全身炎症反应影响的随机试验。
Thromb Haemost. 2017 Aug 30;117(9):1798-1807. doi: 10.1160/TH16-10-0799. Epub 2017 Jul 6.
5
AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol.阿司匹林抑制脓毒症（抗脓毒症）随机对照试验方案。
BMJ Open. 2017 Jan 20;7(1):e013636. doi: 10.1136/bmjopen-2016-013636.
6
P2Y12 Receptor Modulates Sepsis-Induced Inflammation.P2Y12受体调节脓毒症诱导的炎症反应。
Arterioscler Thromb Vasc Biol. 2016 May;36(5):961-71. doi: 10.1161/ATVBAHA.116.307401. Epub 2016 Apr 7.
7
Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.血小板P2Y12抑制剂在实验性人体模型中可减轻全身炎症及其促血栓形成作用。
Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2562-70. doi: 10.1161/ATVBAHA.115.306528. Epub 2015 Oct 29.
8
Coagulation abnormalities in sepsis.脓毒症中的凝血异常。
Acta Anaesthesiol Taiwan. 2015 Mar;53(1):16-22. doi: 10.1016/j.aat.2014.11.002. Epub 2014 Dec 26.
9
Use of antiplatelet agents in sepsis: a glimpse into the future.脓毒症中抗血小板药物的应用：未来一瞥。
Thromb Res. 2014 Feb;133(2):131-8. doi: 10.1016/j.thromres.2013.07.002. Epub 2013 Oct 6.
10
Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: a historical cohort study.接受慢性抗血小板治疗的严重脓毒症和脓毒性休克患者的预后：一项历史性队列研究。
Crit Care Res Pract. 2013;2013:782573. doi: 10.1155/2013/782573. Epub 2013 Feb 20.
Zotero 插件